HER2 Support Group Forums - View Single Post - I thought I was crazy when I noticed a seasonality to bc metastases

Lani · 10-17-2007, 12:12 AM

her2neu breast cancer known to recur sooner and to have a shorter time from recurrence to death than her2- breast cancer --this latter information is included in numerous public lectures given by Dr Slamon

The time from recurrence to death figure he gives is 1 year vs 2 years for nonher2+ bc.

It is still unclear how herceptin changes all this in the long run particularly when given in the adjuvant setting to patients with early bc vs those with metastatic bc (there are many more years of data available in that setting)

I have never seen a graph of how her2+ER+ recurrence compares with
her2+ER- BC, ONLY HOW ER+ RECURS INCOMPARISON WITH ER-. Generally it is accepted that her2+ER+ tumors constitute <10% of ER+ tumors, so a graph of how all ER+ tumors behave may not be that influenced by the subset of those which are her2+ as well.

her2+ER- tumors constitute a larger % of all tumors that are ER-, so their contribution to the survival statistics will be greater and their behavior may more closely resemble those graphs (not entirely clear, but statistically more likely)

10-17-2007, 12:12 AM	#9
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	the peak I was giving was for bc in general as the article was about bc in general her2neu breast cancer known to recur sooner and to have a shorter time from recurrence to death than her2- breast cancer --this latter information is included in numerous public lectures given by Dr Slamon The time from recurrence to death figure he gives is 1 year vs 2 years for nonher2+ bc. It is still unclear how herceptin changes all this in the long run particularly when given in the adjuvant setting to patients with early bc vs those with metastatic bc (there are many more years of data available in that setting) I have never seen a graph of how her2+ER+ recurrence compares with her2+ER- BC, ONLY HOW ER+ RECURS INCOMPARISON WITH ER-. Generally it is accepted that her2+ER+ tumors constitute <10% of ER+ tumors, so a graph of how all ER+ tumors behave may not be that influenced by the subset of those which are her2+ as well. her2+ER- tumors constitute a larger % of all tumors that are ER-, so their contribution to the survival statistics will be greater and their behavior may more closely resemble those graphs (not entirely clear, but statistically more likely)